CXO Talks: Vikas Sharma Reveals QurAlis’ Bold Vision for the Future of Neuroscience

In this episode of CXO Talks, PharmaShots speaks with Vikas Sharma, Chief Business Officer at QurAlis, a biotech company leading the development of precision medicines for neurodegenerative diseases

Vikas discusses the company’s FlexASO platform, a next-generation RNA-targeting technology that tackles the root causes of neurological diseases

Vikas also highlights QurAlis’ lead candidates, QRL-201 and QRL-101, and the impact of its exclusive license agreement with UMass Chan Medical School in strengthening its scientific foundation and expanding its pipeline

Written by

Aditya Singh

Aditya brings a wealth of knowledge and expertise to Pharmashots, having spent his career at top-tier knowledge research and consulting firms. He has a proven track record of success in collaborating with a diverse range of clients, including leading global pharmaceutical and biotechnology companies.

As Editor-in-Chief of Pharmashots, Aditya leverages his deep understanding of the life sciences landscape to curate insightful and impactful content, ensuring readers stay informed about the latest advancements in pharmaceuticals, biotechnology, MedTech, digital health, and the broader life sciences industry.

Connect with Aditya on LinkedIn to stay up-to-date on the latest industry trends and insights.

View all posts by Aditya Singh

CXO Talks: Vikas Sharma Reveals QurAlis’ Bold Vision for the Future of Neuroscience

Aditya Singh

You May Also Like

CXO Talks: Jed Litwiniuk & Uwe Tigör from Auxilius Pharma in a Riveting Dialogue Exchange with PharmaShots

CXO Talks: Ali Jannati from Linus Health in a Stimulating Dialogue Exchange with PharmaShots

CXO Talks: David A. Dodd, Chairman President and CEO of GeoVax Labs Inc. in a riveting conversation with PharmaShots

Contact US

OUR INFORMATION

FOLLOW US